Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centric, Randomized, Pivotal Study, Evaluating Efficacy and Safety of Whole-Body Hyperthermia Alongside Standard Systemic Anticancer Therapy in Patients With Metastatic Pancreatic Cancer After Failure of First Line Treatment.

NCT07711067 is registered in ClinicalTrials.gov with ElmediX as lead sponsor.

NCT NCT07711067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07711067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centric, Randomized, Pivotal Study, Evaluating Efficacy and Safety of Whole-Body Hyperthermia Alongside Standard Systemic Anticancer Therapy in Patients With Metastatic Pancreatic Cancer After Failure of First Line Treatment.
Lead sponsor
ElmediX
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 31, 2030
Enrollment
95 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic ductal adenocarcinoma (pdac), pancreatic ductal adenocarcinoma (mpdac)